Correlation between endothelial dysfunction and left ventricular remodeling in patients with chronic kidney disease

Kidney and Blood Pressure Research

Volumn 39, Issue 5, 2014, Pages 420-426

  Peng, Tao ^a   Hu, Zhao ^a   Wu, Ling ^a   Li, Dengren ^a   Yang, Xiangdong ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Chronic kidney disease; Endothelin 1; Inducible nitric oxide synthase; Nitric oxide; Ventricular remodeling

Indexed keywords

ENDOTHELIN 1; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; BIOLOGICAL MARKER; NOS2 PROTEIN, HUMAN;

ADULT; ARTICLE; CARDIOVASCULAR PARAMETERS; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENDOTHELIAL DYSFUNCTION; ENZYME BLOOD LEVEL; FEMALE; FLOW RATE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART VENTRICLE REMODELING; HUMAN; INCIDENCE; INTERVENTRICULAR SEPTAL THICKNESS; LEFT VENTRICULAR DIASTOLIC DIAMETER; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; BLOOD; HYPERTROPHY, LEFT VENTRICULAR; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC; VASCULAR ENDOTHELIUM;

ADULT; BIOLOGICAL MARKERS; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE II; RENAL INSUFFICIENCY, CHRONIC; VENTRICULAR REMODELING;

EID: 84911493902     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000368455     Document Type: Article

References (19)

1. Moradi H, Sica DA, Kalantar-Zadeh K: Cardiovascular burden associated with uremic toxins in patients with chronic kidney disease. Am J Nephrol 2013;38:136-148
2. Afsar B, Turkmen K, Covic A, Kanbay M: An Update on Coronary Artery Disease and Chronic Kidney Disease. Int J Nephrol 2014;2014:767424
3. Blood Pressure Lowering Treatment Trialists' Collaboration, Ninomiya T, Perkovic V, Turnbull F, Neal B, Barzi F, Cass A, Baigent C, Chalmers J, Li N, Woodward M, MacMahon S: Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: Meta-Analysis of randomised controlled trials. BMJ 2013;347:f5680
4. Aghajanian A, Wittchen ES, Allingham MJ, Garrett TA, Burridge K: Endothelial cell junctions and the regulation of vascular permeability and leukocyte transmigration. J Thromb Haemost 2008;6:1453-1460
5. Prieto D, Contreras C, Sanchez A: Endothelial dysfunction, obesity and insulin resistance. Curr Vasc Pharmacol 2014;12:412-426
6. Toda N, Nakanishi S, Tanabe S: Aldosterone affects blood flow and vascular tone regulated by endotheliumderived NO: Therapeutic implications. Br J Pharmacol 2013;168:519-533
7. Thorin E, Webb DJ: Endothelium-derived endothelin-1. Pflugers Arch 2010;459:951-958
8. Mu J, Feng B, Ye Z, Yuan F, Zeng W, Luo Z, Qi W: Visfatin is related to lipid dysregulation, endothelial dysfunction and atherosclerosis in patients with chronic kidney disease. J Nephrol 2011;24:177-184
9. Eknoyan G: Chronic kidney disease definition and classification: No need for a rush to judgment. Kidney Int 2009;75:1015-1018
10. Devereux RB, Casale PN, Hammond IW, Savage DD, Alderman MH, Campo E, Alonso DR, Laragh JH: Echocardiographic detection of pressure-overload left ventricular hypertrophy: Effect of criteria and patient population. J Clin Hypertens 1987;3:66-78
11. Hallan S, Asberg A, Lindberg M, Johnsen H: Validation of the Modification of Diet in Renal Disease formula for estimating GFR with special emphasis on calibration of the serum creatinine assay. Am J Kidney Dis 2004;44:84-93
12. Palmieri V, Okin PM, de Simone G, Bella JN, Wachtell K, Gerdts E, Boman K, Nieminen MS, Dahlöf B, Devereux RB: Electrocardiographic characteristics and metabolic risk factors associated with inappropriately high left ventricular mass in patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. J Hypertens 2007;25:1079-1085
13. Feng S, Jiang L, Shi Y, Shen H, Shi X, Jin D, Zeng Y, Wang Z: Uric Acid levels and all-cause mortality in peritoneal dialysis patients. Kidney Blood Press Res 2013;37:181-189
14. The Global Burden of Metabolic Risk Factors for Chronic DiseasesCollaboration: Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: A comparative risk assessment. Lancet Diabetes Endocrinol 2014;2:634-647
15. Peterson GE, de Backer T, Contreras G, Wang X, Kendrick C, Greene T, Appel LJ, Randall OS, Lea J, Smogorzewski M,Vagaonescu T, Phillips RA; African American Study of Kidney Disease Investigators: Relationship of left ventricular hypertrophy and diastolic function with cardiovascularand renal outcomes in African Americans with hypertensive chronic kidney disease. Hypertension 2013;62:518-525
16. Unsal A, Kose Budak S, Koc Y, Basturk T, Sakaci T, Ahbap E, Sinangil A: Relationship of Fibroblast Growth Factor 23 with Left Ventricle Mass Index and Coronary Calcificaton in Chronic Renal Disease. Kidney Blood Press Res 2012;36:55-64
17. Ha SK, Park HS, Kim SJ, Park CH, Kim DS, Kim HS: Prevalence and patterns of left ventricular hypertrophy in patients with predialysis chronic renal failure. J Korean Med Sci 1998;13:488-494
18. Dhaun N, Moorhouse R, MacIntyre IM, Melville V, Oosthuyzen W, Kimmitt RA, Brown KE, Kennedy ED, Goddard J, Webb DJ: Diurnal Variation in Blood Pressure and Arterial Stiffness in Chronic Kidney Disease: The Role of Endothelin-1. Hypertension 2014;64:296-304
19. Moningka NC, Tsarova T, Sasser JM, Baylis C: Protective actions of nebivolol on chronic nitric oxide synthase inhibition-induced hypertension and chronic kidney disease in the rat: A comparison with angiotensin II receptor blockade. Nephrol Dial Transplant 2012;27:913-920